Parabolic Drugs

• 

  2 Ashoka University Founders Among 3 Arrested For Alleged Money Laundering

  Two co-founders of the private institution Ashoka University are among three people arrested by the Enforcement Directorate (ED) for alleged money laundering, sources said today.

• 

  Gupta Brothers, Founders Of Ashoka University, Charged With Fraud By CBI

  Pranav Gupta and Vineet Gupta, co-founders of the Ashoka University, have been charged by the CBI for an alleged swindle of Rs 1,626 crore involving their Chandigarh-based pharmaceutical company Parabolic Drugs.

• 

  Case Filed Against Chandigarh-Based Drug Firm For Over Rs 1,600 Crore Fraud

  The CBI has booked top executives of Chandigarh-based Parabolic Drugs Ltd for allegedly defrauding a consortium led by Central Bank of India of Rs 1626.74 crore, officials said Friday.

• Parabolic Drugs Ltd - Result Press Release

  Parabolic Drugs Ltd has informed BSE regarding a Press Release titeld "Q1FY12 Performance".

• Parabolic Drugs Ltd - Board to consider Dividend

  Parabolic Drugs Ltd  has informed BSE that a meeting of the Board of Directors of the Company will be held on August 13, 2011, inter alia, to consider the following: 1. To consider and take on record audited financial results of the Company for the financial year ended March 31, 2011. 2. To consider and take on record the unaudited financial r...

• Parabolic Drugs Ltd - Updates on ensuing Board Meeting on Aug 13, 2011

  With reference to the earlier announcement dated August 05, 2011 regarding the meeting of the Board of Directors of the Company scheduled to be held on August 13, 2011, Parabolic Drugs Ltd has now informed BSE that in the said meeting, the Board will also discuss the issuance of Convertible Warrants on preferential basis to various investors.

• Parabolic Drugs falls below IPO price

  Parabolic Drugs was trading at Rs 72.75 at 9:04 IST on BSE, a 3% discount to the initial public offer price of Rs 75 per share.The stock debuted at Rs 76, a 1.33% premium over the issue price. On BSE, 5.31 lakh shares were traded on the counter. The stock hit a high of Rs 79 and a low of Rs 71.10. The initial public offer of Parabolic Drugs closed ...

• Parabolic Drugs net profit rises 105.71% in the March 2010 quarter

  Sales rise 34.65% to Rs 167.75 croreNet profit of Parabolic Drugs rose 105.71% to Rs 11.52 crore in the quarter ended March 2010 as against Rs 5.60 crore during the previous quarter ended March 2009. Sales rose 34.65% to Rs 167.75 crore in the quarter ended March 2010 as against Rs 124.58 crore during the previous quarter ended March 2009.For the a...

• Parabolic Drugs to debut today

  Parabolic Drugs will make a debut on the secondary market today, 1 July 2010. The company had priced its initial public offer at the lower end of the Rs 75-85 per share IPO price band. The initial public offer of Parabolic Drugs closed with 1.04 times subscription on 17 June 2010 and received bids for 2.77 crore shares as compared to 2.66 crore sha...

• Parabolic Drugs falls below IPO price

  Parabolic Drugs was trading at Rs 72.75 at 9:04 IST on BSE, a 3% discount to the initial public offer price of Rs 75 per share. The stock debuted at Rs 76, a 1.33% premium over the issue price. On BSE, 5.31 lakh shares were traded on the counter. The stock hit a high of Rs 79 and a low of Rs 71.10. The initial public offer of Parabolic...

• Parabolic Drugs - Updates

  Parabolic Drugs Limited has informed the Exchange that the Company has successfully completed the first phase of its expansion programme initiated in 2008 with the commissioning of Multi-Purpose Plant II comprising of 5 manufacturing blocks for parallel production in Derabassi, Punjab. With the commissioning of MP II, the company has added 325 TPA ...

• Parabolic Drugs Limited - Disclosure under Insider Trading Regulation

  Parabolic Drugs Limited has submitted to the Exchange a copy of Disclosure under Section 13(1) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992.

• Parabolic Drugs gets EU GMP approval for its

  Parabolic Drugs gets EU GMP approval for its facility Parabolic Drugs has touched another milestone by receiving European Union approval for its Cephalasporin's manufacturing facility in Derabassi, Punjab. The 27 acre Derabassi manufacturing site of the company, dedicated to manufacturing of Cephalosporin API's and intermediat...

• Parabolic Drugs Limited - Press Release

  Parabolic Drugs Limited has informed the Exchange regarding a press release dated July 12, 2010, titled "Parabolic Drugs Gets EU GMP Approval for its facility".

• Parabolic Drugs Limited - Press Release

  Parabolic Drugs Limited has informed the Exchange vide its letter dated June 30, 2010 regarding a press release with respect to Audited Financial Results of the Company for the quarter / year ended March 31, 2010.